Research Library — FDA | Reta Compare
50 research articles in FDA. Page 1 of 2.
Articles
- FDA Guidance Document on Compounded GLP-1 Drugs (2026 Update)
- FDA Removes Tirzepatide from Drug Shortage List (Recap)
- The FDA 503A Bulks List and Peptides
- The FDA 503B Bulks List and Its Role
- FDA Warning Letters on Compounded Tirzepatide in 2025 and 2026
- FDA Form 483 Observations and What They Mean
- Import Alerts Targeting Compounded GLP-1 API
- The FDA Drug Shortage List: How It Works
- The Role of CDER in Peptide Regulation
- FDA Enforcement Priorities for 2026
- FDA Commissioner Statements on Compounded Peptides
- The 2024 Outsourcing Facilities Association Lawsuit
- Congressional Oversight of FDA Compounded Drug Policy
- FDA Inspection Authority Over Compounding Pharmacies
- The FDA Advisory Committee on Compounding
- FDA and Unapproved New Drug Enforcement
- How FDA Defines 'Essentially a Copy' in Compounding
- The Drug Quality and Security Act at 12 Years
- FDA MedWatch Reports on Compounded GLP-1 Adverse Events
- FDA Import Alert 66-40: What Compounders Should Know
- Counterfeit Semaglutide Seizures in 2025 and 2026
- FDA Policy on Stability Testing for Compounded Peptides
- FDA's Approach to Bulk Drug Substance Nominations
- What Triggers an FDA Inspection of a Compounding Pharmacy
- FDA Enforcement Actions Database: How to Search It